Top Medical Searches

CHMP backs Novartis’s Zykadia for first-line use in lung cancer

ZURICH (Reuters) – Novartis’s push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

 Read more…

Be Sociable, Share!
May 19th, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us